LB Pharmaceuticals, Inc. (LBRX)

37.33 -0.47 (-1.24%) USD  |  NASDAQ  |  Sep 25, 16:00
37.33 0.00 (0.00%) After-Hours: 16:18
More

LB Pharmaceuticals Cash from Operations (TTM) : -82.40M for June 30, 2026

Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for LBRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2024. Start Trial.
Date Value
June 30, 2026 -82.40M
March 31, 2026 -50.37M
December 31, 2025 -35.21M
September 30, 2025 -22.77M
Date Value
June 30, 2025 -41.43M
March 31, 2025 -51.61M
December 31, 2024 -53.05M
September 30, 2024 -48.14M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Ligand Pharmaceuticals, Inc. 131.79M
Neumora Therapeutics, Inc. -180.96M
ANI Pharmaceuticals, Inc. 189.47M
Corcept Therapeutics, Inc. 109.70M
Veru, Inc. -26.04M